Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Deferred Taxes: 2012-2017

Historic Deferred Taxes for Ascendis Pharma A (ASND) over the last 4 years, with Dec 2017 value amounting to $459,199.

  • Ascendis Pharma A's Deferred Taxes rose 82638.51% to $459,199 in Q4 2017 from the same period last year, while for Dec 2017 it was $673,567, marking a year-over-year decrease of 64.62%. This contributed to the annual value of -$3.7 million for FY2018, which is 3885723.08% down from last year.
  • Per Ascendis Pharma A's latest filing, its Deferred Taxes stood at $459,199 for Q4 2017, which was up 315.73% from $110,456 recorded in Q3 2017.
  • In the past 5 years, Ascendis Pharma A's Deferred Taxes registered a high of $23.8 million during Q4 2013, and its lowest value of -$3.9 million during Q2 2014.
  • Its 3-year average for Deferred Taxes is $1.4 million, with a median of $459,199 in 2017.
  • As far as peak fluctuations go, Ascendis Pharma A's Deferred Taxes crashed by 99.98% in 2016, and later skyrocketed by 82,638.51% in 2017.
  • Over the past 5 years, Ascendis Pharma A's Deferred Taxes (Quarterly) stood at $23.8 million in 2013, then slumped by 58.45% to $9.9 million in 2014, then tumbled by 65.92% to $3.4 million in 2015, then slumped by 99.98% to $555 in 2016, then soared by 82,638.51% to $459,199 in 2017.
  • Its Deferred Taxes stands at $459,199 for Q4 2017, versus $110,456 for Q3 2017 and $103,358 for Q2 2017.